Patents by Inventor Sharanjeet Kaur Bagal

Sharanjeet Kaur Bagal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND THEIR USE IN TREATING CANCER
    Publication number: 20230374007
    Abstract: The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where A, Z, Y, RA, Linker and v have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts thereof in methods of treatment of the human or animal body, for example in the prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 23, 2023
    Inventors: Iacovos Neal Michaelides, Ulf Börjesson, Thomas George Christopher Hayhow, Jason Grant Kettle, Gavin William Collie, Robert Ian Storer, Christoph Grebner, Matthew William Dampier Perry, Sharanjeet Kaur Bagal, Charlene Fallan
  • Tetracyclic heteroaryl compounds
    Patent number: 11407765
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: August 9, 2022
    Assignee: AstraZeneca, AB
    Inventors: Jason Grant Kettle, Sharanjeet Kaur Bagal, Andrew John Eatherton, Shaun Michael Fillery, Graeme Richard Robb, Scott Gibson Lamont, Paul David Kemmitt, Frederick Woolf Goldberg
  • HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
    Publication number: 20220127281
    Abstract: The specification relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 28, 2022
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
  • TETRACYCLIC HETEROARYL COMPOUNDS
    Publication number: 20210221823
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 7, 2019
    Publication date: July 22, 2021
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Scott Gibson LAMONT, Paul David KEMMITT, Frederick Woolf GOLDBERG
  • HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS
    Publication number: 20200109153
    Abstract: The specification relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof. The specification also relates to processes and intermediates used for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 9, 2020
    Inventors: Jason Grant KETTLE, Sharanjeet Kaur BAGAL, Scott BOYD, Andrew John EATHERTON, Shaun Michael FILLERY, Graeme Richard ROBB, Piotr Antoni RAUBO
  • N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS
    Publication number: 20170305857
    Abstract: The present invention relates to compounds of Formula (I) described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 26, 2017
    Applicant: Pfizer Limited
    Inventors: SARAH ELIZABETH SKERRATT, SHARANJEET KAUR BAGAL, NIGEL ALAN SWAIN, KIYOYUKI OMOTO, MARK DAVID ANDREWS
  • Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
    Publication number: 20170197939
    Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Application
    Filed: April 1, 2015
    Publication date: July 13, 2017
    Applicant: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • N-Acylpyrrolidine Ether Tropomyosin-Related Kinase Inhibitors
    Publication number: 20160221989
    Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: August 4, 2015
    Publication date: August 4, 2016
    Applicant: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Jingrong Jean Cui, Samantha Elizabeth Greasley, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Michelle Bich Tran-Dubé
  • Tropomyosin-related kinase inhibitors
    Patent number: 9328096
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • TROPOMYOSIN-RELATED KINASE INHIBITORS
    Publication number: 20150322043
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Application
    Filed: May 6, 2015
    Publication date: November 12, 2015
    Inventors: SHARANJEET KAUR BAGAL, JINGRONG JEAN CUI, SAMANTHA ELIZABETH GREASLEY, ELIZABETH ANN LUNNEY, INDRAWAN JAMES MCALPINE, ASAKO NAGATA, SACHA NINKOVIC, KIYOYUKI OMOTO, SARAH ELIZABETH SKERRATT, ROBERT IAN STORER, JOSEPH SCOTT WARMUS
  • Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
    Patent number: 9163021
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: October 20, 2015
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150250785
    Abstract: The present invention relates to compounds of Formula (IA) and (IB) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 10, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Sarah Elizabeth Skerratt
  • Pyrrolo[3,2-C]Pyridine Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150246912
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: September 3, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Wolfgang Klute, Inaki Morao, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
    Publication number: 20150218172
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: September 26, 2013
    Publication date: August 6, 2015
    Applicant: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, David Graham Brown, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Yogesh Sabnis, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • (4-phenylimidazol-2-yl) ethylamine derivatives useful as sodium channel modulators
    Patent number: 9079878
    Abstract: The present invention is directed to imidazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new imidazole NaV1.8 modulators of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. NaV1.8 modulators are useful in the treatment of a wide range of disorders, particularly pain.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: July 14, 2015
    Assignee: Pfizer Limited
    Inventors: Sharanjeet Kaur Bagal, Mark Ian Kemp, Duncan Charles Miller, Yoshihisa Murata
  • Chemical compounds
    Patent number: 8927587
    Abstract: The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7. X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: January 6, 2015
    Assignee: Pfizer LImited
    Inventors: Sharanjeet Kaur Bagal, Alan Daniel Brown, Mark Ian Kemp, Wolfgang Klute, Laia Malet Sanz, Brian Edward Marron, Duncan Charles Miller, Sarah Elizabeth Skerratt, Mark J. Suto, Christopher William West
  • PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
    Publication number: 20140364415
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicant: PFIZER LIMITED
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • (4-Phenylimidazol-2-yl) Ethylamine Derivatives Useful As Sodium Channel Modulators
    Publication number: 20140296313
    Abstract: The present invention is directed to imidazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new imidazole NaV1.8 modulators of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as defined in the description. NaV1.8 modulators useful in the treatment of a wide range of disorders, particularly pain.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 2, 2014
    Applicant: Pfizer Limited
    Inventors: Sharanjeet Kaur Bagal, Mark Ian Kemp, Duncan Charles Miller, Yoshihisa Murata
  • Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors
    Patent number: 8846698
    Abstract: The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: September 30, 2014
    Assignee: Pfizer Limited
    Inventors: Mark David Andrews, Sharanjeet Kaur Bagal, Karl Richard Gibson, Kiyoyuki Omoto, Thomas Ryckmans, Sarah Elizabeth Skerratt, Paul Anthony Stupple
  • Chemical Compounds
    Publication number: 20130274243
    Abstract: The invention relates to benzimidazole and imidazopyridine derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to new Nav1.8 modulators of formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the description. Nav1.8 modulators are potentially useful in the treatment of a wide range of disorders, particularly pain.
    Type: Application
    Filed: January 29, 2013
    Publication date: October 17, 2013
    Inventors: Sharanjeet Kaur Bagal, Alan Daniel Brown, Mark Ian Kemp, Wolfgang Klute, Laia Malet Sanz, Brian Edward Marron, Duncan Charles Miller, Sarah Elizabeth Skerratt, Mark J. Suto, Christopher William West